ISRCTN51336867已完成不适用
The effects of metformin on vascular function and adipocyte AMP-activated protein kinase (AMPK) activation in type 2 diabetes: a randomised, double blind, glycaemia-controlled crossover trial
Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)0 个研究点目标入组 20 人开始时间: 2010年6月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Body mass index (BMI) range 27 - 40 kg/m2
- •2. HbA1c greater than 7% but less than 11% (Diabetes Control and Complications Trial [DCCT]) at screening
- •3. Previously treated with diet alone or oral monotherapy (i.e., metformin or sulphonylurea). Subjects on monotherapy had discontinued medication during the six-week run-in period.
- •4. Males, aged between 50 - 70 years
排除标准
- •1. Subjects on warfarin treatment
- •2. Subjects treated with insulin currently or in the previous 12 months
- •3. Previous intolerance of metformin or sulphonylurea
- •4. Presence of contra-indication to metformin therapy for example renal disease or congestive cardiac failure
- •5. Cardiovascular event (i.e., electrocardiogram (ECG)/troponin proven myocardial infarction [MI] or cerebrovascular accident [CVA]) in previous 6 months
研究者
相似试验
招募中
4 期
Investigating the effect of metformin on vascular function and cardiovascular risk factors in children and adolescents with type 1 diabetesType 1 diabetes mellitusIRCT20230930059564N1Shahid Beheshti University of Medical Sciences52
已完成
2 期
The Effects of Metformin on Blood Vessel Structure and FunctionObesityHypertensionHypercholesterolemiaHyperglycemiaNCT00105066National Institute on Aging (NIA)77
招募中
4 期
Does Metformin improve vascular function in youth with Type 1 diabetesType 1 diabetesVascular healthMetabolic and Endocrine - DiabetesCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemDiet and Nutrition - ObesityObesityACTRN12611000148976Alexia Pena76
进行中（未招募）
1 期
The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo - Use of Metformin following weight loss and improvement in CV riskImpaired fasting glucoseMedDRA version: 9.1Level: LLTClassification code 10056997Term: Impaired fasting glucoseEUCTR2008-004497-40-GBHull and East Yorkshire Hospitals NHS Trust
已完成
不适用
Addition of metformin to growth hormone for short children born small for gestational ageISRCTN19548431Hospital Sant Joan de Deu (Spain)64